Abstract
Introduction: Short term studies of Elexacaftor/tezacaftor/ivacaftor (ETI) have shown increasing weight gain and modest improvements in GI symptoms. Since August 2020, all CF patients aged >12 years attending our Paediatric Service have been treated with ETI according to UK licencing. In this real-world study, we assessed changes in nutritional status after starting ETI, effects on the need for enteral feeding, use of pancreatic enzymes (PERT), endocrine function and medication.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
